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Action of Linezolid or Vancomycin on Biofilms in
Ventriculoperitoneal Shunts In Vitro
Roger Bayston, Gautham Ullas, and Waheed Ashraf
Biomaterials-Related Infection Group, School of Clinical Sciences, University of Nottingham School of Medicine and Health Sciences, Nottingham, United Kingdom
Cerebrospinal fluid (CSF) shunts used to treat hydrocephalus have an overall infection rate of about 10% of operations. The
commonest causative bacteria are Staphylococcus epidermidis, followed by Staphylococcus aureus and enterococci. Major diffi-
culties are encountered with nonsurgical treatment due to biofilm development in the shunt tubing and inability to achieve suf-
ficiently high CSF drug levels by intravenous administration. Recently, three cases of S. epidermidis CSF shunt infection have
been treated by intravenous linezolid without surgical shunt removal, and we therefore investigated vancomycin and linezolid
against biofilms of these bacteria in vitro. A continuous-perfusion model of shunt catheter biofilms was used to establish mature
(1-week) biofilms of Staphylococcus aureus, Staphylococcus epidermidis (both methicillin resistant [MRSA and MRSE]), Entero-
coccus faecalis, and Enterococcus faecium. They were then “treated” with either vancomycin or linezolid in concentrations
achievable in CSF for 14 days. The biofilms were thenmonitored for 1 week for eradication and for regrowth. Enterococcal bio-
films were not eradicated by either vancomycin or linezolid. Staphylococcal biofilms were eradicated by both antibiotics after 2
days and did not regrow. No resistance was seen. Linezolid at concentrations achievable by intravenous or oral administration
was able to eradicate biofilms of both S. epidermidis (MRSE) and S. aureus (MRSA). Neither vancomycin at concentrations
achievable by intrathecal administration nor linezolid was able to eradicate enterococcal biofilms. It is hoped that these in vitro
results will stimulate further clinical trials with linezolid, avoiding surgical shunt removal.
Since their introduction in the 1950s, hydrocephalus shuntshave been subject to infection, which has seriously compro-
mised their benefit. Despite general and specific improvements in
infection control, approximately 10% of shunt procedures result
in infection (11). This rate is higher when infants under 6 months
of age are shunted (22).Most shunt infections are caused by staph-
ylococci, with the Staphylococcus epidermidis group predominat-
ing, followed by Staphylococcus aureus. Less commonly,Enterococ-
cus spp. are involved (7, 17). Historically, staphylococcal shunt
infections were treated with long courses of intravenous anti-
staphylococcal antibiotics, such asmethicillin (8), with no success.
Methicillin was undetectable in the cerebrospinal fluid (CSF), but
even intraventricular administration was unsuccessful, and the
shunts had to be removed to effect a cure. Little has changed since
in therapy of shunt infections, with attempts to treat themwithout
shunt removal showing poor results (1, 18). There are two main
reasons for this. First, most shunt infections are associated with a
low-grade inflammatory response in the ventricular system, and
most antibiotics when administered intravenously do not pene-
trate the blood-CSFbarrier sufficiently to provide therapeuticCSF
concentrations. Second, the seat of a shunt infection is inside the
shunt tubing itself. The causative bacteria attach to the shunt sur-
face and develop a biofilm, a situation that became apparent only
in 1972 (4) but which has been confirmed since (12, 16). Biofilms
are complex communities of bacteria that have adopted a dor-
mant mode in order to survive. As almost all antibiotics act on
synthetic systems of actively multiplying bacteria, these biofilm
bacteria become insusceptible to therapy (13). There are therefore
two reasons for treatment failure in shunt infections. Current rec-
ommendations are to remove or externalize the shunt and to give
intravenous antibiotics until the CSF is clear of infection before
considering shunt replacement. The guidelines of the British So-
ciety for Antimicrobial Chemotherapy (BSAC) (27) suggest using
intraventricular vancomycin in order to ensure adequate CSF
concentrations, and for staphylococcal infections, this usually al-
lows reshunting where necessary within about 10 to 14 days, but
regimens vary considerably, and long hospital stays with relapse
are not infrequent (20).
Recently, intravenous linezolid has shown value in treating
posttraumatic meningitis due to multiresistant S. epidermidis,
where over 90% serum concentrations of the drug were detected
in the CSF despite minimal ventricular inflammatory response
(21, 29). There are few reports in the literature of the use of lin-
ezolid in shunt infections (9, 10, 14, 15, 17, 26, 28, 29), and in only
three cases (9, 28) was the infection treated without shunt re-
moval. In these three cases (two due to methicillin-resistant S.
epidermidis [MRSE] and one to methicillin-resistant S. aureus
[MRSA]), cure was achieved.
This led us to investigate the ability of therapeutically achiev-
able CSF linezolid concentrations to eradicate biofilms of staphy-
lococci and enterococci using an established in vitro model of
shunt colonization (3). (G. Ullas submitted part of this work in
fulfillment of the requirements for the degree of Bachelor ofMed-
ical Science from the University of Nottingham School of Medi-
cine and Health Sciences, Nottingham, United Kingdom.)
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MATERIALS AND METHODS
Test bacteria. Strains of MRSA and MRSE and of Enterococcus faecium
and Enterococcus faecalis, both susceptible to vancomycin, were used. The
MRSA, MRSE, and E. faecium strains were from shunt infections; the E.
faecalis strain was from a urinary-catheter-related infection, as a shunt
isolate was not available. All test strains were shown by microtiter plate
assay to be biofilm producers. The test strains were characterized and
antimicrobial susceptibilities were determined by standard methods, in-
cluding determination of MICs by Etest (AB Biodisk, Solna, Sweden).
In vitro challenge model. The in vitro challenge model was a modifi-
cation of an established apparatus that we have used previously to study
biofilm growth in shunt catheters and its prevention (3). The modifica-
tions were to hardware and pumps and did not change the fundamental
design. Briefly, 35-cm lengths of medical-grade silicone tubing of the type
used in hydrocephalus shunt catheters were sterilized by autoclaving and
aseptically introduced into controlled-environment tubes tomaintain hy-
dration and a temperature of 37°C. Eachwas aseptically connected distally
to an outlet tube draining to waste and proximally to an inlet tube. This
was then connected via a peristaltic pump to a reservoir containing tryp-
tone soy broth (TSB) (Oxoid, Basingstoke, United Kingdom). The test
catheters were perfused with TSB at a rate of 20 ml/hour, approximating
the CSF production rate. Control catheters were set up identically except
for the antibiotics.
Bacterial challenge.Cultures of the test bacteria were prepared in TSB
by incubation on an orbital shaker at 200 rpm for 5 h. The resulting
suspension was then diluted to give 108 CFU/ml, and 1 ml of this was
aseptically injected into the relevant test catheter. The catheter was
clamped for 1 h to allow bacterial attachment, and perfusion was then
restarted.
Monitoring of biofilm development and treatment effects. Samples
were taken daily to ensure establishment of biofilms, and quantitative
cultures were carried out. On day 7, the antibiotics were introduced to the
reservoir (representing the ventricle), and perfusion was continued for 14
days, followed by a 7-day antibiotic-free perfusion. Each day, a 1-ml sam-
ple was taken from the distal end of each test catheter after aseptic discon-
nection of the outlet tube, and after vortexmixing, 200l was spread over
a blood agar plate and incubated for 48 h at 37°C for colony counting.
Where samples were visibly cloudy, appropriate dilutions were made be-
fore plating. When there was no decrease in counts; where there were
persistent positive cultures over the treatment period, indicating failure;
or when regrowth occurred, the identities and MICs of the isolates were
checked.
Antibiotic dosing. Concentrations of each antibiotic in the reservoir
(“ventricle”) were calculated to reflect those achieved after intravenous
administration (linezolid) or intraventricular administration (vancomy-
cin). The concentrationswere as follows: vancomycin, 50mg/liter (2), and
linezolid, 5 mg/liter (5). Vancomycin hydrochloride was purchased from
Wockhardt Ltd., Wrexham, United Kingdom, and linezolid from Phar-
macia Ltd., Sandwich, United Kingdom.
All colonized catheters were treated with linezolid or vancomycin. All
antibiotic treatment was continued for 2 weeks, after which perfusion was
switched to plain TSB for the detection of regrowth.
Assay of antibiotic activity. Samples from each ventricle were taken at
day 7, day 8, and day 21 to determine whether the drugs were still fully
active. Standards for each drug weremade, and the samples were tested by
the agar dilution bioassay technique using a laboratory strain of S. epider-
midis.
RESULTS
TheMICs of the antibiotics for the test bacteria are shown inTable
1. All were susceptible to linezolid and vancomycin.
The results of treatment with each drug regimen are shown in
Fig. 1 to 4. In the case of E. faecium, vancomycin appeared to
eradicate colonization, but regrowth occurred. Though bacterial
counts were considerably reduced, linezolid did not eradicate E.
faecium, and regrowth occurred. Neither linezolid nor vancomy-
cin eradicated E. faecalis. Both linezolid and vancomycin eradi-
cated S. epidermidis within 3 days, and no regrowth occurred. In
the case ofMRSA, both drug treatments eradicated the biofilms in
2 days, and no regrowth occurred. No resistance was seen to either
of the antibiotics.
Bioassay of vancomycin and linezolid concentrations before,
TABLE 1 MICs of linezolid and vancomycin for test bacteria
Bacteriuma
MIC (mg/liter)
Linezolid Vancomycin
MRSA 1.0 2.0
MRSE 0.5 2.0
E. faecalis 1.0 4.0
E. faecium 1.0 4.0
a E. faecalis and E. faecium were vancomycin susceptible.
FIG 1 MRSA. Days 1 to 7, biofilm growth and maturation; days 8 to 21,
treatment; days 22 to 28, regrowth/relapse phase. Control biofilm, solid line;
linezolid, dotted line; vancomycin, dashed line. Linezolid and vancomycin
eradicated colonization on day 9 (day 2 of treatment), and there was no re-
growth. The error bars indicate standard deviations.
FIG 2 Methicillin-resistant S. epidermidis. Days 1 to 7, biofilm growth and
maturation; days 8 to 21, treatment; days 22 to 28, regrowth/relapse phase.
Control biofilm, solid line; linezolid, dotted line; vancomycin, dashed line.
Linezolid and vancomycin eradicated colonization on day 9 (day 2 of treat-
ment), and therewas no regrowth. The error bars indicate standard deviations.
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during, and at the end of the perfusion period showed no reduc-
tion in antimicrobial activity (data not shown).
DISCUSSION
Current treatment of shunt infection depends on shunt removal
and intravenous antibiotics, often extending to several weeks. It
can be complicated by secondary infections during external ven-
tricular drainage to control intracranial pressure and by failure to
eradicate the intracranial infection before reshunting. The rein-
fection rate has been reported to be 15% (25), and each reinfection
requires another round of shunt removal, intravenous antibiotics,
and reshunting. In some cases, several attempts are necessary in
order to establish a functioning, uninfected shunt, and in such
cases, there is evidence of poorer outcome. Intravenous adminis-
tration of most of the common antimicrobials does not reliably
lead to therapeutic antibiotic levels in the CSF (1, 19, 23, 24).
Intraventricular antibiotic administration involves a risk of intro-
duction of infection, and administration of some antibiotics by
this route is not possible due to neurotoxicity. In almost all stud-
ies, even when intraventricular administration has been used,
shunt removal has still been necessary. This is because the seat of
the infection is bacterial colonization of the shunt tubing with
biofilm formation. Toour knowledge, only one study has reported
the consistently successful use of a nonsurgical approach based on
intravenous and intraventricular antibiotics (6). The treatment
failed in only 2 of 30 patients with coagulase-negative staphylo-
coccus (CoNS) shunt infections, though the regimen was not use-
ful for S. aureus infections. For enterococcal infections, intraven-
tricular gentamicin was added to the vancomycin. In each case, a
contralateral reservoir was inserted for ventricular access. We
could find no other reports of the successful use of this regimen in
other hands.Obviously, if a regimenwere available that eradicated
shunt colonization without shunt removal, and preferably with-
out intraventricular administration of antibiotics, it would be a
significant therapeutic advance. Linezolid achieves therapeutic
CSF concentrations when administered intravenously (21, 29).
For eradication of the biofilms in the shunt, concentrations in
excess of the MIC are required, and these have been shown to be
achievable (17).
The BSAC guidelines (27) recommend the use of intraventric-
ular vancomycin, and this is acknowledged to be more effective
than intravenous administration (1, 2, 24). The results of this in
vitro investigation show that both vancomycin and linezolid, at
concentrations found in CSF and under flow conditions, are ac-
tive against biofilms of S. epidermidis and methicillin-resistant S.
aureus, but not against those of E. faecalis or E. faecium. While
both vancomycin and linezolid were able to reduce the enterococ-
cal biofilms, only linezolid reduced the effluent counts to zero, and
in all cases, even with linezolid, they regrew during the relapse
phase. It is possible that longer treatment with linezolid would
have led to their eradication. The staphylococcal biofilms were
apparently eradicated and did not regrow during the relapse
phase. The effluent counts have been shown to closely reflect the
biofilm density in the catheters (3), but where they fall to zero, a
period of antibiotic-free perfusion is necessary to exclude their
persistence and subsequent regrowth. In clinical terms, this
would, of course, lead to treatment failure with relapse after ces-
sation of treatment.
The results suggest that both linezolid and vancomycin might
be effective against staphylococcal shunt infections without shunt
removal. The advantage of linezolid over vancomycin is that ther-
apeutic CSF levels can be achieved by intravenous administration,
while vancomycin must be administered intraventricularly to ob-
tain the CSF levels used here, and it may be necessary to insert a
contralateral reservoir for this purpose to ensure success (6). The
possibility has also been raised of reverting to oral linezolid ther-
apy, perhaps even as an outpatient, subject to the patient’s general
condition. Further clinical trials of the use of linezolid for nonsur-
gical treatment of staphylococcal shunt infections should be stim-
ulated by these results. However, it should be recognized that the
data were generated using an in vitro system, and while they sup-
port previous clinical findings, they should be interpreted with
caution.
FIG 4 E. faecium. Days 1 to 7, biofilm growth and maturation; days 8 to 21,
treatment; days 22 to 28, regrowth/relapse phase. Control biofilm, solid line;
linezolid, dotted line; vancomycin, dashed line. Linezolid and vancomycin
reduced colonization between days 8 and 21, but this was not eradication, and
growth increased again during the relapse phase. The error bars indicate stan-
dard deviations.
FIG 3 E. faecalis. Days 1 to 7, biofilm growth and maturation; days 8 to 21,
treatment; days 22 to 28, regrowth/relapse phase. Control biofilm, solid line;
linezolid, dotted line; vancomycin, dashed line. Linezolid and vancomycin
reduced colonization between days 8 and 21, but this was not eradication, and
growth increased again during the relapse phase. The error bars indicate stan-
dard deviations.
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